Gentis news

                        Array
(
    [0] => stdClass Object
        (
            [id] => 1300
            [id_crawler] => 
            [category_product] => NULL
            [thumbnail] => 6e65830d266c9532cc7d.jpg
            [album] => 
            [url_video] => 
            [is_status] => 1
            [is_featured] => 0
            [is_form] => 0
            [displayed_time] => 2025-04-09
            [program] => 0
            [number] => 1
            [viewed] => 0
            [type] => 
            [type_career] => 
            [level] => 
            [address] => 
            [address_career] => 
            [expiration_time] => 0000-00-00
            [created_time] => 2025-04-09 09:16:44
            [updated_time] => 2025-09-08 15:13:26
            [files] => 
            [salary] => 
            [time] => 
            [created_by] => 63
            [is_table_content] => 1
            [language_code] => en
            [slug] => Gentis-accompanies-the-art-advanced-12-conference-new-perspectives-on-reproductive-science-from-clinical-data-to-personalized-treatment
            [title] => GENTIS accompanies the ART ADVANCED 12 Conference: “New perspectives on reproductive science: from clinical data to personalized treatment”
            [description] => The ART ADVANCED 12 conference is a significant scientific event in the field of reproductive support organized by the Hanoi Reproductive Support Association. With the theme “New Perspectives on Reproductive Science: From Clinical Data to Personalized Treatment,” the conference will provide in-depth updates and important discussions about advances in reproductive support. This is an opportunity for experts to meet, share experiences, and move towards personalized treatment to improve clinical practice outcomes.
            [content] => 
This year’s conference will take place on Friday, April 18, 2025, at the Pan Pacific Hotel Hanoi (1 Thanh Nien Road, Ba Dinh, Hanoi).

We are honored to accompany the conference as a sponsor. GENTIS’ booth will offer many exciting activities and attractive gifts for delegates. Additionally, the GENTIS booth will focus on presenting solutions for genetic screening and diagnosis in the field of reproductive support, particularly the three new PGT testing packages: PGT +100 rare diseases, PGT NEXT, and PGT UPGRADE.
One of the key advantages of PGT-M testing at GENTIS is the ability to analyze over 100 single-gene genetic diseases with high accuracy, allowing for the detection of even small DNA variants that may cause disease. By applying next-generation sequencing (NGS) technology combined with family-specific marker design, PGT-M ensures accuracy in identifying healthy embryos, thus increasing the chances of having a child free from genetic disorders. In addition to advanced technology, PGT-M for 100+ rare diseases also includes support from a dedicated genetic counseling team, accompanying patients before, during, and after testing.
PGT NEXT is a pre-embryo transfer genetic test capable of detecting aneuploidy on 24 chromosomes, additional abnormalities, and chromosomal deletions. It can also detect embryos with triploidy or monosomy. This helps avoid transferring embryos with these abnormalities, while also preventing wasting euploid embryos that have fertilization issues (0PN, 1PN, and 2.1/3PN). Additionally, PGT NEXT provides genetic information for embryo selection prior to transfer.
The combination of whole-genome sequencing (NGS) with SNP analysis enhances the resolution of genetic screening to detect aneuploidy. This method allows for the detection of monosomic and trisomic chromosomes, increasing the number of euploid embryos available for transfer by identifying truly diploid embryos among abnormal fertilized embryos (0PN, 1PN, 2.1PN, 3PN). Furthermore, SNP analysis ensures accurate identification of whether an embryo shares a genetic relationship with other embryos in the same group, reducing the risk of sample mix-ups due to procedural errors.
PGT UPGRADE is a pre-embryo transfer genetic test capable of detecting aneuploidy on 24 chromosomes, additional abnormalities, chromosomal deletions larger than 5 Mb, and particularly the ability to detect balanced translocations inherited from parents. Additionally, PGT UPGRADE provides genetic information for embryo selection before transfer.

At the conference, Dr. Pham Dinh Minh (Director of R&D at GENTIS) will present a report titled: "Factors Affecting the Outcome of Mosaic Embryos from a Genetic Lab Perspective."
We cordially invite doctors, embryologists, and experts to visit the GENTIS booth to update themselves on the most modern and advanced pre-implantation genetic screening solutions, serving the healthcare needs of the Vietnamese people.
            [content_more] => 
            [meta_title] => GENTIS accompanies the ART ADVANCED 12 Conference: “New perspectives on reproductive science: from c
            [meta_description] => The ART ADVANCED 12 conference is a significant scientific event in the field of reproductive support organized by the Hanoi Reproductive Support Association. 
            [meta_keyword] => GENTIS,Conference
            [thumbnail_alt] => 
            [post_id] => 1300
            [category_id] => 14
        )

    [1] => stdClass Object
        (
            [id] => 1299
            [id_crawler] => 
            [category_product] => NULL
            [thumbnail] => ảnh-5913.jpg
            [album] => 
            [url_video] => 
            [is_status] => 1
            [is_featured] => 0
            [is_form] => 0
            [displayed_time] => 2025-04-09
            [program] => 0
            [number] => 1
            [viewed] => 0
            [type] => 
            [type_career] => 
            [level] => 
            [address] => 
            [address_career] => 
            [expiration_time] => 0000-00-00
            [created_time] => 2025-04-09 09:11:03
            [updated_time] => 2025-09-08 15:13:32
            [files] => 
            [salary] => 
            [time] => 
            [created_by] => 63
            [is_table_content] => 1
            [language_code] => en
            [slug] => Gentis-honored-at-the-vietnam's-number-1-brand-2025-announcement-ceremony
            [title] => GENTIS honored at the Vietnam's Number 1 Brand 2025 announcement ceremony
            [description] => At the Vietnam’s Number 1 Brand 2025 announcement ceremony organized by the Asian Business Development Research Center, Genetic Analysis Services Joint Stock Company (GENTIS) was honored with the “Vietnam’s Number 1 Brand 2025” award in the genetic analysis field - Gold category, as well as the “Best Medical Product/Service for Consumers in 2025” award for the PGT-Max 1 test.
            [content] => 
GENTIS Confirms its Position with the Vietnam’s Number 1 Brand 2025 Award in Genetic Analysis - Gold Category
The Vietnam’s Number 1 Brand announcement ceremony is an annual program organized by the Asian Business Development Research Center. The event aims to encourage and honor businesses and entrepreneurs who have continuously strived, overcome market challenges, and made positive contributions to the community, thereby fostering the country’s economy in the new era - the Era of National Growth.
The awards are selected based on international quality standards for businesses with high-quality products and services. To be recognized for the award, products must meet strict criteria, including: being a leading brand in the industry; having products and services widely recognized by consumers; demonstrating sustainable development strategies; contributing to the economy; complying with environmental, tax, customs, intellectual property, and labor regulations; and demonstrating social and community responsibility.
In addition, depending on the industry sector, the selection committee will evaluate specific criteria: capabilities; management philosophy; technology and innovation activities; financial capacity; human resources; marketing strategies, etc. GENTIS excellently met these criteria and proudly received the Gold category “Vietnam’s Number 1 Brand 2025” award in the Genetic Analysis field.
Mr. Pham Dinh Minh (R&D Director of GENTIS) Receives the Gold Cup and Certificate for Vietnam’s Number 1 Brand 2025 in Genetic Analysis
This award is a testament to the quality of GENTIS’s tests on the market and the trust and loyalty of its customers towards the GENTIS brand. It also serves as motivation for the company to continue delivering even more value to its partners and customers.
Looking at its development journey, it is evident that GENTIS has always been at the forefront of making new advancements in applying technology and building a comprehensive genetic testing ecosystem that caters to a wide range of customers. GENTIS’s product and service ecosystem continues to expand and diversify, including services for assisted reproduction, obstetrics and gynecology, andrology, hematology - immunology, oncology - pediatrics, and family testing.
Furthermore, to increase partner and customer satisfaction, GENTIS consistently focuses on improving and optimizing the testing process to save costs for patients. GENTIS also strengthens training efforts to improve the professional skills, knowledge, and expertise of its staff to meet the increasing demands of the job.
GENTIS understands that customer satisfaction comes not only from good products and services but also from comprehensive, attentive care experiences. GENTIS will continue to strive to bring more value to the community.
GENTIS Awarded Vietnam’s Number 1 Brand 2025 in Genetic Analysis - Gold Category
PGT-Max 1 Test - A Technological Breakthrough in Pre-implantation Genetic Testing
At the Vietnam’s Number 1 Brand 2025 announcement ceremony, GENTIS’s PGT-Max 1 test was honored in the “Best Medical Product/Service for Consumers” category. This is a significant milestone for GENTIS in asserting the quality of the PGT-Max 1 test.
According to experts, genetic disorders in assisted reproduction are increasingly on the rise. One method to detect genetic abnormalities in embryos is Pre-implantation Genetic Testing for Aneuploidy (PGT-Max 1). PGT-Max 1 is a pre-implantation genetic test that helps select embryos without chromosomal abnormalities (24 chromosomes), without additional mutations, or chromosomal segment deletions, optimizing the embryo selection process before IVF (in vitro fertilization), ensuring that the child born is healthy and free of the genetic abnormalities detected.
GENTIS’s PGT-Max 1 Test Recognized as the Best Medical Product/Service for Consumers in 2025
GENTIS has successfully optimized and applied the PGT-Max 1 test on embryos for many infertile couples hoping for a child. Thanks to the PGT-Max 1 test, doctors and experts can select embryos with good genetic quality, increasing the chances of successful implantation during IVF, ensuring that the child is born healthy and free from the genetic abnormalities screened.
At GENTIS, the PGT-Max 1 test is performed using advanced technologies, including NGS sequencers from Illumina (USA) and specialized bioinformatics software, with the highest sensitivity and specificity of up to 99.9%. GENTIS will also continue to strive to develop and deliver the most advanced and safest genetic testing solutions as part of its mission to enhance the physical and intellectual well-being of the Vietnamese people.
The Vietnam’s Number 1 Brand 2025 award in Genetic Analysis and the Best Medical Product/Service for Consumers in 2025 for the PGT-Max 1 test marks a milestone acknowledging GENTIS’s contributions. This will serve as motivation for GENTIS to continue its mission to “enhance the intellect and health of the Vietnamese people” in the future.
            [content_more] => 
            [meta_title] => GENTIS honored at the Vietnam's Number 1 Brand 2025 announcement ceremony
            [meta_description] => At the Vietnam’s Number 1 Brand 2025 announcement ceremony organized by the Asian Business Development Research Center, Genetic Analysis Services Joint Stock Company (GENTIS) was honored with the “Vietnam’s Number 1 Brand 2025” award in the genetic analys
            [meta_keyword] => GENTIS,Awards,PGT MAX 1
            [thumbnail_alt] => 
            [post_id] => 1299
            [category_id] => 14
        )

    [2] => stdClass Object
        (
            [id] => 1298
            [id_crawler] => 
            [category_product] => NULL
            [thumbnail] => 3-min.jpg
            [album] => 
            [url_video] => 
            [is_status] => 1
            [is_featured] => 0
            [is_form] => 1
            [displayed_time] => 2025-04-09
            [program] => 0
            [number] => 1
            [viewed] => 0
            [type] => 
            [type_career] => 
            [level] => 
            [address] => 
            [address_career] => 
            [expiration_time] => 0000-00-00
            [created_time] => 2025-04-09 08:21:08
            [updated_time] => 2025-09-08 15:13:42
            [files] => 
            [salary] => 
            [time] => 
            [created_by] => 63
            [is_table_content] => 1
            [language_code] => en
            [slug] => Gentis-collaborates-with-the-department-of-andrology-and-sexology-hanoi-university-of-medicine-to-organize-a-scientific-seminar
            [title] => GENTIS collaborates with the Department of Andrology and Sexology - Hanoi University of Medicine to organize a scientific seminar
            [description] => Recently, GENTIS collaborated with the Department of Andrology and Sexology at Hanoi University of Medicine to successfully organize a scientific seminar aimed at helping doctors and healthcare staff gain a better understanding of two specialized test packages: Whole Exome Sequencing (WES) and Sperm DNA Fragmentation.

            [content] => 
The seminar at Hanoi University of Medicine was attended by numerous experts and doctors from the Department of Andrology and Sexology, such as Associate Prof. Dr. Nguyen Hoai Bac (Head of the Department), MSc. Dr. Tran Van Kien, MSc. Dr. Do Ich Dinh, MSc. Dr. Chu Thi Chi, and MSc. Dr. Nguyen Cao Thang. From GENTIS, the seminar was attended by MSc. Hoang Thi Nhung (Head of R&D) and MSc. NT. Vu Thu Huong (R&D Specialist).

At the beginning of the seminar, MSc. NT. Vu Thu Huong explained that high levels of sperm DNA fragmentation are one of the causes of male infertility. There are many factors that lead to sperm fragmentation. According to MSc. NT. Vu Thu Huong, Sperm DNA testing is an essential method for evaluating the overall quality of a patient's sperm. This test helps quantify the percentage of sperm DNA fragmentation by detecting color changes in a dye through a flow cytometry system (which analyzes up to 10,000 sperm), helping identify the cause of infertility in cases where the semen analysis result is normal.
In addition, the sperm DNA fragmentation test can also explain repeated miscarriages, unexplained infertility, and failed IVF attempts. Therefore, evaluating sperm quality through sperm DNA fragmentation testing is extremely necessary, as it helps doctors predict fertility potential and determine the most suitable intervention for assisted reproduction.
At GENTIS, sperm DNA fragmentation (Sperm DNA) tests are conducted using the SCSA (Sperm Chromatin Structure Assay) method, ensuring high stability, accuracy, and performance.
A unique feature of this test is the clear categorization of sperm DNA fragmentation thresholds. This helps doctors better screen cases of unexplained infertility, thus guiding treatment intervention.
In addition to the Sperm DNA fragmentation test, the seminar also featured a discussion of new information about the Whole Exome Sequencing (WES) test. According to MSc. Hoang Thi Nhung (GENTIS), WES is a DNA sequencing method aimed at analyzing the entire protein-coding region, or Exons, in the human genome. GENTIS uses next-generation sequencing (NGS) technology on the NovaSep 6000 system to sequence the entire exon region of around 22,000 genes (covering over 85% of disease-causing mutations). This allows for the detection of point mutations, small deletions/inserts, and CNVs. Whole Exome Sequencing provides the ability to diagnose genetic diseases of unknown causes, particularly rare and complex diseases, and detect genetic variants associated with neurological, cardiovascular, and other conditions.

Through the discussion, doctors from the Department of Andrology and Sexology at Hanoi University of Medicine highly appreciated the significant improvements in WES and Sperm DNA testing and posed many in-depth questions regarding these two tests. This demonstrates the interest of medical professionals in GENTIS’s WES and Sperm DNA tests. We hope that after this scientific seminar, GENTIS will continue to have the opportunity to collaborate and work with Hanoi University of Medicine in the future!
            [content_more] => 
            [meta_title] => GENTIS collaborates with the Department of Andrology and Sexology - Hanoi University of Medicine to 
            [meta_description] => Recently, GENTIS collaborated with the Department of Andrology and Sexology at Hanoi University of Medicine to successfully organize a scientific seminar aimed at helping doctors and healthcare staff gain a better understanding of two specialized test pac
            [meta_keyword] => GENTIS,SPERM DNA,WES
            [thumbnail_alt] => 
            [post_id] => 1298
            [category_id] => 14
        )

    [3] => stdClass Object
        (
            [id] => 1295
            [id_crawler] => 
            [category_product] => NULL
            [thumbnail] => 487932123_1057582843073573_1848132115822519272_n.jpg
            [album] => 
            [url_video] => 
            [is_status] => 1
            [is_featured] => 0
            [is_form] => 0
            [displayed_time] => 2025-04-01
            [program] => 0
            [number] => 1
            [viewed] => 0
            [type] => 
            [type_career] => 
            [level] => 
            [address] => 
            [address_career] => 
            [expiration_time] => 0000-00-00
            [created_time] => 2025-04-01 08:49:27
            [updated_time] => 2025-09-08 15:13:58
            [files] => 
            [salary] => 
            [time] => 
            [created_by] => 63
            [is_table_content] => 1
            [language_code] => en
            [slug] => Happy-motherhood-journey-prenatal-class-equipping-expectant-mothers-with-useful-knowledge
            [title] => "Happy Motherhood Journey" Prenatal Class - Equipping Expectant Mothers with Useful Knowledge
            [description] => Recently, the 5th-floor hall of Hanoi Andrology and Fertility Hospital collaborated with the Happy Home AF HANOI Association successfully chaired the “Happy Motherhood Journey” prenatal class. GENTIS was honored to accompany the event as a sponsor.
            [content] => 
The class attracted participation of more than expectant mothers, bringing a professional and warm ambience filled with valuable insights. The prenatal class featured MSc. Dr. Hoang Van Khanh and specialist doctor level 1 Luu Ba Hung - specialists in Obstetrics and Gynecology at the Hanoi Andrology and Fertility Hospital.

With years of experiences and an amiable sharing style, the two doctors had provided useful answers related to common issues faced during pregnancy. This helped the mothers have better preparations physically and mentally for the journey of pregnancy and childbirth.

During the interactive Q&A section, a lot of practical questions were asked covering topics such as signs of preterm labor, recognizing labor contractions, and concerns regarding nutritions. The doctors not only answered the questions thoughtfully, but also shared real-life stories from their experiences treating expectant mothers, helping them better understand the challenging but joyful journey of motherhood.

The class concluded in a warm and emotional atmosphere. Not only the expectant mothers gained invaluable knowledge, but also they received meaningful gifts from the organizers as a loving reminder of the sacred journey of parenthood. 
In the future, GENTIS, in partnership with the hospital, will continue to organize more prenatal classes to accompany families in preparing a solid foundation for the arrival of their beloved babies.

            [content_more] => 
            [meta_title] => "Happy Motherhood Journey" Prenatal Class - Equipping Expectant Mothers with Useful Knowledge
            [meta_description] => Recently, the 5th-floor hall of Hanoi Andrology and Fertility Hospital collaborated with the Happy Home AF HANOI Association successfully chaired the “Happy Motherhood Journey” prenatal class. GENTIS was honored to accompany the event as a sponsor.
            [meta_keyword] => GENTIS,Prenatal class,Expectant mothers
            [thumbnail_alt] => 
            [post_id] => 1295
            [category_id] => 14
        )

    [4] => stdClass Object
        (
            [id] => 1294
            [id_crawler] => 
            [category_product] => NULL
            [thumbnail] => dsc02289.jpg
            [album] => 
            [url_video] => 
            [is_status] => 1
            [is_featured] => 0
            [is_form] => 0
            [displayed_time] => 2025-03-26
            [program] => 0
            [number] => 1
            [viewed] => 0
            [type] => 
            [type_career] => 
            [level] => 
            [address] => 
            [address_career] => 
            [expiration_time] => 0000-00-00
            [created_time] => 2025-03-26 10:33:26
            [updated_time] => 2025-09-08 15:15:31
            [files] => 
            [salary] => 
            [time] => 
            [created_by] => 63
            [is_table_content] => 1
            [language_code] => en
            [slug] => Application-of-pgt-m-tests-in-thalassemia-genetic-disorder-screening
            [title] => Application of PGT-M tests in Thalassemia genetic disorder screening
            [description] => Thalassemia is a recessive inherited anemia disorder on the autosomal chromosome, with the highest incidence rates globally, including in Vietnam. Thalassemia causes severe consequences for the material and mental well-being of affected individuals and their families. Currently, there is no definitive cure for this disease, but proactive prevention and screening are possible. Notably, the advent of Preimplantation Genetic Testing for Monogenic Disorders (PGT-M) helps reduce the risk of having children affected by Thalassemia.
            [content] => 
Thalassemia – A Recessive Genetic Disorder to Be Aware Of
Thalassemia (also known as congenital hemolysis) is the most common single-gene genetic disorder worldwide. According to reports from the Thalassemia Federation and WHO in 2008, approximately 7% of the global population carries the disease gene. For every 100 couples, about 1.1 couples are at risk of having a child with the disease or carrying the Thalassemia gene.
Dr. Le Thao Ly (Quang Ninh Obstetrics and Pediatrics Hospital) reported at the 2025 Clinical Embryology Conference.
In Vietnam, Thalassemia is the leading cause of severe anemia and hemolysis in children. According to the Vietnam Congenital Hemolysis Association, there are about 12 million carriers of the disease gene, and an estimated 20,000 patients need treatment each year.
Couples who carry the Thalassemia gene have a 50% chance of having a child who carries the gene and a 25% chance of having a child with the disease if they conceive naturally. Therefore, couples planning for pregnancy, especially those with a family history of Thalassemia, should take preventive measures for the future generation by undergoing screening for early detection and appropriate preventive actions using PGT-M.
PGT-M Testing Helps Thalassemia-Carrying Parents Have Healthy Children
According to Dr. Le Thao Ly (Quang Ninh Obstetrics and Pediatrics Hospital), who presented at the 6th CEC Conference, PGT-M (Preimplantation Genetic Testing for Monogenic Gene Disorders) was first reported in 1990 and was originally used to diagnose genetic disorders linked to the X chromosome. With this technique, we can examine the genetic makeup of embryos at a very early stage, identifying specific abnormal gene segments inherited from the parents.
As a result, embryos with the disease-causing gene are eliminated before being transferred to the mother's uterus. The effectiveness of this method has been proven to help reduce the incidence of children born with the disease and minimize the need for pregnancy termination.
PGT-M plays a crucial role in reproductive medicine but still presents some challenges.
PGT-M is a test that identifies single-gene abnormalities and mutations related to genetic syndromes such as Thalassemia, Spinal Muscular Atrophy (SMA), Hemophilia, Rett Syndrome, Polycystic Kidney Disease, and others. It is recommended for couples carrying disease-causing gene mutations who are at high risk of having a child with a monogenic genetic disorder.
PGT-M is a highly accurate technique, requiring advanced technology such as SNP (Single Nucleotide Polymorphism) analysis, STR (Short Tandem Repeat) analysis, qPCR (real-time PCR), MLPA (Multiplex Ligation-dependent Probe Amplification), or NGS (Next-Generation Sequencing), depending on the specific monogenic disorder to be analyzed. The goal is to detect gene mutations that the parents carry and can pass on to their child.
To perform PGT-M, couples typically need reproductive assistance through in vitro fertilization (IVF). Embryos created through IVF are cultured until day 5. Embryos at this stage (blastocysts) are biopsied, and 5-7 cells are extracted from the part of the embryo that will develop into the placenta. These cell samples undergo special tests to identify the disease-causing genes.
This test enables doctors to check the genetic makeup of the embryos at an early stage, allowing for the identification and removal of embryos carrying the parents' genetic disease. Only healthy embryos are transferred to the mother's uterus, increasing the chances of pregnancy and resulting in healthy children who do not carry genetic mutations for future generations.
To date, in addition to screening for Thalassemia PGT-M, GENTIS has also developed PGT-M techniques for over 100 rare genetic disorders, including Duchenne Muscular Dystrophy, Spinal Muscular Atrophy, Hemophilia, Congenital Adrenal Hyperplasia, and more.
PGT-M Testing at GENTIS is Performed Using a Rigorous, Professional Process
Along with the application of new technologies and advanced machinery systems (Veriseq PGS technology, Illumina NGS DNA sequencing system from the USA, and SNP, STR analysis methods), PGT-M testing at GENTIS is carried out in a strict, professional manner to ensure highly reliable results. Combining PGT-M screening for monogenic genetic disorders with PGT-A/SR testing before PGT-M helps provide a comprehensive assessment of embryo quality, improving the success rate of assisted reproductive methods.
            [content_more] => 
            [meta_title] => Application of PGT-M tests in Thalassemia genetic disorder screening
            [meta_description] => Thalassemia is a recessive inherited anemia disorder on the autosomal chromosome, with the highest incidence rates globally, including in Vietnam. Thalassemia causes severe consequences for the material and mental well-being of affected individuals and th
            [meta_keyword] => GENTIS,Thalassemia,PGT-M
            [thumbnail_alt] => 
            [post_id] => 1294
            [category_id] => 14
        )

    [5] => stdClass Object
        (
            [id] => 1293
            [id_crawler] => 
            [category_product] => NULL
            [thumbnail] => 79de34c95adeea80b3cf.jpg
            [album] => 
            [url_video] => 
            [is_status] => 1
            [is_featured] => 0
            [is_form] => 0
            [displayed_time] => 2025-03-25
            [program] => 0
            [number] => 1
            [viewed] => 0
            [type] => 
            [type_career] => 
            [level] => 
            [address] => 
            [address_career] => 
            [expiration_time] => 0000-00-00
            [created_time] => 2025-03-25 08:43:38
            [updated_time] => 2025-09-08 15:15:43
            [files] => 
            [salary] => 
            [time] => 
            [created_by] => 63
            [is_table_content] => 1
            [language_code] => en
            [slug] => PGT-M-for-100+-rare-diseases-a-solution-for-healthy-babies-in-families-carrying-genetic-disorders
            [title] => PGT-M for 100+ Rare Diseases: A Solution for Healthy Babies in Families Carrying Genetic Disorders
            [description] => Rare diseases often lead to serious health complications and significantly affect a patient’s quality of life. Therefore, the development of PGT-M testing to screen and select embryos free of rare disease-causing genes for implantation is essential. In an effort to eliminate the fear of rare diseases from the community, GENTIS has researched and developed a PGT-M test capable of screening for over 100 rare diseases.
            [content] => 
Rare Diseases – A Group That Demands Attention
Rare diseases are conditions that occur infrequently in the general population, usually caused by genetic mutations, and often have a severe impact on a patient’s health. According to the World Health Organization (WHO), a disease is considered rare when it affects fewer than 1 in 2,000 people. While each disease is rare individually, over 7,000 rare diseases have been identified, affecting approximately 300 million people worldwide.
These diseases are typically serious due to their complex nature and the lack of effective treatments. Many manifest severely from birth, leading to congenital defects, developmental delays, high mortality rates, or lifelong disabilities. Because of the low prevalence, developing treatments and diagnostics remains a major challenge, limiting access to care.
However, advancements in genetics, assisted reproduction, and prenatal diagnostics have expanded our ability to screen and manage rare diseases, offering hope for couples wanting to conceive and give birth to healthy children.
PGT-M for 100+ Rare Diseases: Bringing Hope to Families with Genetic Risks
In clinical practice and research, medical genetics plays an increasingly vital role. Preimplantation Genetic Testing for Monogenic Disorders (PGT-M), combined with assisted reproductive technologies, has brought joy to many infertile couples by allowing them to have healthy children and contribute to reducing the incidence of monogenic rare diseases in the community.
PGT-M is performed during in vitro fertilization (IVF) and is used to detect and select embryos free from disease-causing genetic mutations before embryo transfer into the uterus
GENTIS Utilizes Modern Technologies for PGT-M Testing
PGT-M plays a key role in screening and preventing rare diseases, especially in couples with a family history of genetic conditions. By ensuring that only embryos without the disease-causing gene are transferred, this test not only reduces the burden of genetic disease on families but also improves the overall health of future generations.
Applying PGT-M in assisted reproduction marks a significant breakthrough in medicine, offering hope and a path forward for couples who wish to have healthy children, while reducing the risk of passing on rare genetic diseases.
At GENTIS, PGT-M can detect over 100 rare diseases caused by gene mutations, helping minimize the risk of giving birth to a child with a severe genetic disorder.
A Highly Skilled Team at GENTIS
Outstanding Advantages of the PGT-M Test for 100+ Rare Diseases:
This specialized test not only brings hope to couples carrying genetic disorders but also offers multiple advantages for optimizing genetic screening right from the embryonic stage.
One of the most significant benefits of GENTIS’s PGT-M test is the ability to accurately analyze over 100 monogenic disorders, capable of detecting even subtle variations in DNA that may cause disease.
Using next-generation sequencing (NGS) technology combined with customized family-specific marker design, PGT-M ensures precise identification of healthy embryos, increasing the chances of a successful, healthy pregnancy.
Additionally, the PGT-M service for 100+ rare diseases is supported by a team of expert genetic counselors, who guide patients before, during, and after the testing process.
Expert-Led, Patient-Centered Genetic Counseling at GENTIS
Before testing, counselors help couples understand their genetic risks, explain disease mechanisms, and assess the necessity of the test. Throughout the testing process, experts closely monitor each stage to ensure result accuracy and appropriateness.
After results are available, the team continues to provide support by interpreting clinical implications, guiding couples in selecting the best embryos, and proposing tailored reproductive strategies if necessary.
Thus, PGT-M is more than a screening tool — it is a comprehensive solution, offering peace of mind to families at risk of transmitting genetic conditions.
According to Assoc. Prof. Dr. Francesca Spinella (Former Chair of the ESHRE PGT Consortium and Genetic Consultant at Eurofins GENTIS), PGT-M plays a vital role in the field of reproductive medicine. This test allows for the screening of monogenic disorders and ensures that only embryos without genetic mutations are transferred — bringing hope to couples struggling with infertility and genetic risks.
            [content_more] => 
            [meta_title] => PGT-M for 100+ Rare Diseases: A Solution for Healthy Babies in Families Carrying Genetic Disorders
            [meta_description] => Rare diseases often lead to serious health complications and significantly affect a patient’s quality of life. Therefore, the development of PGT-M testing to screen and select embryos free of rare disease-causing genes for implantation is essential
            [meta_keyword] => GENTIS,pgt-m
            [thumbnail_alt] => 
            [post_id] => 1293
            [category_id] => 14
        )

    [6] => stdClass Object
        (
            [id] => 1292
            [id_crawler] => 
            [category_product] => NULL
            [thumbnail] => dsc02511.jpg
            [album] => 
            [url_video] => 
            [is_status] => 1
            [is_featured] => 0
            [is_form] => 0
            [displayed_time] => 2025-03-24
            [program] => 0
            [number] => 1
            [viewed] => 0
            [type] => 
            [type_career] => 
            [level] => 
            [address] => 
            [address_career] => 
            [expiration_time] => 0000-00-00
            [created_time] => 2025-03-24 16:00:41
            [updated_time] => 2025-09-08 15:15:50
            [files] => 
            [salary] => 
            [time] => 
            [created_by] => 63
            [is_table_content] => 1
            [language_code] => en
            [slug] => GENTIS-accompanies-the-2025-clinical-embryology-conference
            [title] => GENTIS Accompanies the 2025 Clinical Embryology Conference
            [description] => Clinical embryology and issues related to the IVF lab play a vital role in the advancement of Assisted Reproductive Technology (ART). The 6th Clinical Embryology Conference (CEC), organized by the Ho Chi Minh City Society for Reproductive Medicine (HOSREM), will be held on March 22–23, 2025. The conference aims to provide opportunities for professional updates, knowledge exchange, and the presentation of scientific research in the field of clinical embryology. GENTIS is honored to be a sponsor of this important event.
            [content] => 
At the conference, leading experts in IVF will present and discuss various issues related to clinical embryology and IVF laboratories. Some of the key topics covered include:


Quality management and new techniques



Embryo genetic testing


Sperm-related factors


Poor prognosis cases


Embryo culture and cryopreservation


Embryos from abnormal fertilization and abnormal oocytes



Notably, GENTIS is proud to have provided PGT-M testing data for the presentation by Resident Doctor Lê Thảo Ly (Quang Ninh Obstetrics and Pediatrics Hospital), titled: "Evaluating the Live Birth Rate Following Preimplantation Genetic Testing for Monogenic Disorders (PGT-M) for Thalassemia at Quang Ninh Obstetrics and Pediatrics Hospital from 2022–2024."
According to Dr. Thảo Ly, Thalassemia is the most common autosomal recessive inherited anemia worldwide, including in Vietnam. This disease significantly impacts the physical and mental well-being of patients and their families. While there is currently no definitive cure, it can be proactively prevented and screened. Importantly, the introduction of PGT-M has helped reduce the risk of giving birth to children affected by Thalassemia.
At GENTIS, the PGT-M test is conducted using cutting-edge technologies and modern equipment, including Veriseq PGS, next-generation sequencing (NGS) with Illumina technology (USA), and SNP/STR analysis methods. This ensures the high reliability of test results. Currently, GENTIS is capable of screening for more than 100 monogenic diseases using PGT-M.

As a sponsor of the conference, GENTIS presented an impressive booth with a variety of engaging activities, drawing great interest from many delegates. Highlights included:


Introducing advanced, modern solutions for preimplantation embryo genetic screening tailored to improve healthcare outcomes for the Vietnamese population, particularly two new PGT testing packages: PGT NEXT and PGT UPGRADE



Providing the latest genetic testing materials in the field of assisted reproduction


Offering attractive appreciation gifts to participating delegates



Over the years, GENTIS has regularly participated in conferences and seminars to stay updated with the latest insights, technologies, and advancements in IVF. Our goal is to provide effective and accurate genetic testing for patients.
The 2025 Clinical Embryology Conference concluded successfully, offering a wealth of knowledge, clinical expertise, and updates on trends, technologies, and treatment protocols. It also signals promising growth in Vietnam’s reproductive health sector in the years ahead.
            [content_more] => 
            [meta_title] => GENTIS Accompanies the 2025 Clinical Embryology Conference
            [meta_description] => Clinical embryology and issues related to the IVF lab play a vital role in the advancement of Assisted Reproductive Technology (ART). The 6th Clinical Embryology Conference (CEC), organized by the Ho Chi Minh City Society for Reproductive Medicine (HOSREM
            [meta_keyword] => gentis,CEC
            [thumbnail_alt] => 
            [post_id] => 1292
            [category_id] => 14
        )

    [7] => stdClass Object
        (
            [id] => 1290
            [id_crawler] => 
            [category_product] => NULL
            [thumbnail] => b7db2d93bf200e7e5731.jpg
            [album] => 
            [url_video] => 
            [is_status] => 1
            [is_featured] => 0
            [is_form] => 0
            [displayed_time] => 2025-03-18
            [program] => 0
            [number] => 1
            [viewed] => 0
            [type] => 
            [type_career] => 
            [level] => 
            [address] => 
            [address_career] => 
            [expiration_time] => 0000-00-00
            [created_time] => 2025-03-18 15:58:16
            [updated_time] => 2025-09-08 15:16:11
            [files] => 
            [salary] => 
            [time] => 
            [created_by] => 63
            [is_table_content] => 1
            [language_code] => en
            [slug] => https://gentis.com.vn/tin-tuc-c4/gentis-gioi-thieu-xet-nghiem-pgt-next-va-pgt-upgrade-tai-benh-vien-buu-dien-d1290
            [title] => GENTIS introduces 2 new PGT test packages at Hospital of Post and Telecommunications
            [description] => On the afternoon of March 6, GENTIS coordinated with the Post Office Hospital to organize a seminar introducing two newly launched PGT testing packages: PGT NEXT and PGT UPGRADE. Throughout the seminar, GENTIS representatives discussed and answered questions from doctors at the Post Office Hospital about these new genetic testing packages.
            [content] => 
Attending the seminar, on behalf of the IVF Center, the Post Office Hospital had the presence of Master. Doctor Bach Huy Anh (Deputy Director), Master. Doctor Chu Thi Huong, Doctor CKI. Kieu Duc Ty and doctors of the department. Representing GENTIS, there was the participation of Mr. Nguyen Quang Vinh (Director of Testing Center) and Mr. Nguyen Van Huynh (Leader of R&D).
Mr. Vinh and Mr. Huynh gave a detailed introduction to the two test packages PGT NEXT and PGT UPGRADE of GENTIS. Sharing with the doctors of the HTSS Center - Post Office Hospital, Mr. Huynh emphasized the technological breakthrough of both new PGT tests.

Accordingly, the PGT NEXT test is a test that can detect haploid/polyploid embryos. According to statistics during the research process at GENTIS: "Haploid/polyploid abnormalities occur in 1-3% of all pregnancies and triploidy accounts for 15-18% of miscarriages." Therefore, detecting haploid/polyploid embryos is highly significant in increasing the success rate of IVF.
In addition, PGT NEXT also supports and complements PGT-A/SR, helping to detect polyploid embryos and identify embryos with normal diploid chromosome sets, even in abnormally fertilized embryos (e.g., 0PN, 1PN, or 2.1/3PN).
This test can be extended to patients with a history of polyploidy, molar pregnancy, and miscarriage after IVF combined with traditional PGT-A, increasing the number of embryos that can be transferred from abnormally fertilized zygotes (0PN, 1PN, or 2.1/3PN). The implementation process combines whole genome sequencing NGS (Low-pass sequencing) with targeted SNP sequencing to detect polyploidy.

For PGT UPGRADE, this is a test to detect embryos carrying balanced translocations. "Balanced translocation is the phenomenon of exchanging DNA segments between non-homologous chromosomes without increasing or decreasing genetic material at the breakpoints. In balanced translocation, there are also two types: Reciprocal translocation and Robertsonian translocation."
The PGT UPGRADE test is indicated for couples with a history of recurrent miscarriage, a family history of chromosomal abnormalities, or spouses carrying balanced translocations who do not want to pass them on to the next generation. The implementation process combines whole genome sequencing NGS (Low-pass sequencing) with targeted SNP sequencing to detect embryos carrying balanced translocations.
The outstanding advantage of the PGT NEXT and PGT UPGRADE tests is the use of specialized bioinformatics software optimized specifically for the Vietnamese population. Therefore, these two tests not only help detect genetic abnormalities but also help reduce the risk of miscarriage, increase the success rate of in vitro fertilization (IVF) and help select healthy embryos to be placed in the uterus.

At the end of the presentation, doctors at the Post Office Hospital asked many questions about PGT NEXT and PGT UPGRADE, specifically: "Is 18% of the total number of embryos the proportion of euploid embryos carrying balanced translocations?", "With this new technology, is the cost of performing PGT UPGRADE much higher than the cost of performing PGT-A?". Thanks to the detailed answers of the GENTIS representative, the doctors had a clearer view and could visualize the future development of the PGT NEXT and PGT UPGRADE tests.

The seminar took place in a very exciting atmosphere and received a lot of attention and positive feedback from the participating doctors. Master, Doctor Bach Huy Anh shared: "Thank you GENTIS for coming to our hospital today and updating new products that are extremely meaningful and highly practical. For me personally, the PGT UPGRADE test has a high humanitarian significance, helping couples with balanced translocation genes prevent the possibility of passing it on to future generations. I believe that in the future, these two tests will greatly support infertile couples with multiple miscarriages, helping them reach their dream of becoming parents."
            [content_more] => 
            [meta_title] => GENTIS introduces 2 new PGT test packages at Hospital of Post and Telecommunications
            [meta_description] => On the afternoon of March 6, GENTIS coordinated with the Post Office Hospital to organize a seminar introducing PGT NEXT and PGT UPGRADE.
            [meta_keyword] => gentis,Pgtnext,Pgtupgrade
            [thumbnail_alt] => 
            [post_id] => 1290
            [category_id] => 14
        )

)